TIMP2 and acute kidney injury: Based on Sapphire and Topaz study, the urine compound of TIMP-2 and IGFBP-7 became the first US Food and Drug Administration (FDA)-approved biomarker for risk assessment of AKI in ICU patients in 2014 (Us Food and Drug Administ, 2014).